SCD affects approximately 100,000 US individuals, and 300,000 births annually worldwide, largely on the African continent. While it is a genetic hemoglobinopathy, SCD is a systemic disorder. In the lungs, nearly every cell type and structure are affected, and cardiopulmonary complications are a leading cause of morbidity and accelerated mortality. The goal of this scientific symposium is to present recent findings and evidence-based interventions for acute and chronic pulmonary complications of SCD across the lifespan. We will actively engage pediatric and adult clinicians and researchers to promote collaborative investigation and implementation of evidence-based clinical care for patients living with SCD.
• Define the current state-of-the-art management of the acute and chronic pulmonary complications of sickle cell disease and identify knowledge gaps that exist
• Understand the impact of abnormalities throughout the pulmonary system (airway, gas exchange/sleep, and vascular) as disease modifiers on SCD outcomes throughout the lifespan
• Gain an understanding of the mechanisms of new SCD disease-modifying therapies including hematopoietic stem cell transplantation and gene therapy on overall disease progression and potential impacts on cardiopulmonary dysfunction
Robyn Cohen, MD, MPH
Andrew Campbell, MD
Shaina Willen, MD
Olufunke Afolabi-Brown, MD
Elizabeth Klings, MD
Courtney Fitzhugh, MD
A Patient's Perspective
SCD and SCD-Modifying Therapies: A Pulmonary Perspective
Airway Function in SCD: Impact on Morbidity and Mortality Across the Lifespan
Sleep Disordered Breathing in SCD - What Have We Learned?
Acute Chest Syndrome and Venous Thromboembolism in SCD: When the Acute Becomes Chronic
Curative Therapies for Sickle Cell Disease: Potential Cures for SCD but What About the Lung?